Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis

Infectious Diseases in Clinical Practice

Volumn 7, Issue 2, 1998, Pages 101-109

  Habib, Michael P ^a,f   Gentry, Layne O ^b   Rodriguez Gomez, Guillermo ^c   Morowitz, William ^d   Polak, Elaine ^e   Rae, Jena K ^e   Morgan, Nancy S ^e   Williams, R Rex ^e  

^a UNIVERSITY OF ARIZONA   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c Cariblanco Hydroelectric Project   (Costa Rica)

^d Delaware Valley Clinical Research   (United States)

^e R W JOHNSON PHARMACEUTICAL RES I   (United States)

^f SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFACLOR; LEVOFLOXACIN;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0031934272     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199802000-00009     Document Type: Article

References (29)

1. U.S. Department of Commerce, Bureau of the Census. Statistical abstract of the United States. 113th ed. Washington (DC): U.S. Government Printing Office; 1993.
2. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1984;78(6B Suppl):45S-51S.
3. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases. 3rd ed. New York: John Wiley; 1990. p. 531.
4. Gump DW, Phillips CA, Forsyth BR, et al Role of infection in chronic bronchitis. Am Rev Respir Dis 1976;113: 465-74.
5. Pollard JA, Wallace RJ Jr, Nash DR, et al. Incidence of Branhamella catarrbalis in the sputa of patients with chronic lung disease. Drugs 1986;3(31 Suppl):103S-108S.
6. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204
7. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis: a controlled study using tetracycline. Ann Intern Med 1982;97:18-21.
8. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. JAMA 1995;273:957-60.
9. Med Lett 1992;34.
10. Archer GL, Polk RE. Treatment and prophylaxis of bactenal infections. In: Isselbacher KJ, Braunwald E, Wilson J, editors. Harrison's principles of internal medicine. 13th ed Vol. 1. New York: McGraw-Hill, 1994. p. 600.
11. Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992,36:860-6.
12. Fujimoto T, Mitsuhashi S. In vitro antibacterial activity of DR-3355. the s-(-) isomer of ofloxacin. Chemotherapy 1990;36:268-76.
13. Une T, Fujimoto T, Sato K. et al. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 1988;32:1336-40.
14. Klugman KP, Capper T, Bryskier A. In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin. fusidic acid, and rifampin. Antimicrob Agents Chemother 1996;40:2802-4
15. Markus A, Isert D, Kiesel N, et al. Killing activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in vitro and in vivo [abstract]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 17-20, 1995, San Francisco. Washington (DC): American Society for Microbiology; 1995. p. 90.
16. Baltch AL, Smith RP, Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob Agents Chemother 1995; 39 1661-6.
17. Chow AW, Hall CB, Klein JO. et al. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis 1992;15(1 Suppl):62S-88S.
18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. M2-A3. Villanova (PA): National Committee for Clinical Laboratory Standards; 1983.
19. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Villanova (PA): National Committee for Clinical Laboratory Standards: 1988.
20. Hauck W, Anderson S. A comparison of large sample confidence interval methods for the difference of two binomial probabilities. Am Stat 1986;40:318-22.
21. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy [letter]. N Engl J Med 1991;325:520-1.
22. Nolen TM, Phillips HL, Hutchison J, et al. Comparison of cefuroxime axetil and cefaclor for patients with lower respiratory tract infections presenting to a rural family practice clinic. Curr Ther Res Clin Exp 1988;44:821-9.
23. Schleupner CJ, Anthony WC, Tan J, et al. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Arch Intern Med 1988;148:343-8.
24. Guay DR, Craft JC. Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J Intern Med 1992;231:295-301.
25. Kayser FH Changes in the spectrum of organisms causing respiratory tract infections: a review. Postgrad Med J 1992:68(3 Suppl):17-23.
26. Chechani V, Allam AA, Smith PR, et al. Bronchitis mimicking opportunistic lung infection in patients with human immunodeficiency virus infection/AIDS. NY State J Med 1992;92:297-300.
27. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108(Suppl):43S-52S.
28. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146: 1067-83.
29. DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin vs. cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997;42:206-13.